RCC tumor xenografts developed resistance to PT2399 when treated for over 100 days, which may be mediated by a G323E mutation in EPAS1 (endothelial PAS domain-containing protein 1) encoding for HIF-2α [20]. The gene discussed is EPAS1; the disease is neoplasm.